Adaptive Research: A Path to Efficacy and Efficiency

February 12, 2015

CfPA-The Center for Professional Advancement, New Brunswick, NJ
August 26-27, 2015

Who Should Attend?
This course is intended for professionals in the Pharmaceutical, Biopharmaceutical and Medical Device industries. Participants who work in the clinical trial arena and who currently wish to add efficacy and efficiency to their clinical trials will highly benefit from this seminar. This course will intensively cover the use of adaptive technique to all stages of product development and will add exceptional knowledge in identifying the causes of costly and nonproductive research. Those professionals who will benefit from this course will be in such areas as:

  • Manufacturing and distribution
  • Regulatory
  • Protocol development
  • Medical and clinical monitoring
  • Biostatistics
  • Toxicology and other pre-clinical departments

Course Description

In an era of ever rising costs and development of sophisticated therapeutics to meet the needs of the healthcare population, a new technique entitled “Adaptive Approach” has come to the forefront. No longer can clinical development be done in the old fashioned way of trial and error as the costs and risks are too high. The adaptive approach is now being used to identify and more importantly eliminate these costly and unproductive errors. This 2-day comprehensive training will apply the adaptive approach to therapeutic development, and in doing so will give to the participant the ability to use this approach as the new baseline for development of a product.

Maximize Your Learning!
Attend this course and its Companion Course:
Medical Device: Meeting Development and Global Regulatory Challenges
August 24-25, 2015 • New Brunswick, NJ • Course ID #2092

Organized by:

CfPA-The Center for Professional Advancement

Invited Speakers:

Bart Chapman MD MBA FAAO

Bart Chapman, MD MBA FAAO, a board certified physician with over 30 successful years in the medical device industry, has been involved in IDEs, 510K clearance and PMAs and directing clinical trials through all phases of development for medical devices.

His role has varied from developing Phase I-IV protocols and implementing them to overseeing strategic marketing and distribution of numerous medical devices on an international basis and in accordance with global regulatory standards.

He has secured sophisticated SABs for medical device development and created strategic protocols for meeting ISO 13485 standards as well as EU directives. As a physician investigator, Doctor Chapman has been intricately involved in both medical device therapeutics as well as diagnostic devices. As a pharmacovigilence medical director, he has been responsible for safety measurements of medical devices both pre and post clearance and in meeting with CDRH panels.

Dr. Chapman brings a wealth of knowledge and experience in the medical device arena both from a regulatory point of view as well as a clinician.

Deadline for Abstracts:

n/a

Registration:

Please click here for registration information.

E-mail:

sberg@cfpa.com

home

genetic news

bioinformatics

biotechnology

literature

journals

ethics

positions

events

sitemap